Your session is about to expire
← Back to Search
Control for Inflammatory Bowel Disease (PATH-IBD Trial)
PATH-IBD Trial Summary
This trial is testing whether using behavioral science principles can help improve patient engagement and communication between office visits for people with inflammatory bowel disease.
- Inflammatory Bowel Disease
- Crohn's Disease
- Ulcerative Colitis
PATH-IBD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPATH-IBD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 4 trial • 200 Patients • NCT01342510PATH-IBD Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Can elderly subjects aged 75 and up enroll in this trial?
"This clinical trial is seeking out individuals between 18 and 65 years of age."
To whom is this clinical research opportunity available?
"Penn Gastroenterology is currently seeking 150 volunteers aged between 18 and 65 suffering from ileocolitis. Eligibility requires that they receive at least one of the following biologics: infliximab, adalimumab, ustekinumab, certolizumab, golimumab or vedolizumab - although not restricted to new initiators. Additionally, participants must have had two visits with Penn Gastroenterology in the last 2 years."
Are there any openings left for potential participants in this research endeavor?
"As indicated on clinicaltrials.gov, this trial is no longer recruiting participants after being initially posted in February 2021 and last updated in September 2022. Nevertheless, there are presently 536 other medical trials actively searching for patients to enrol."
Share this study with friends
Copy Link
Messenger